Lovastatin Trial Targeted Neurofibromatosis Symptoms
Researchers studied the effects of the drug on brain oscillations in a group of 15 individuals.
Updated on Oct. 6, 2026 in Autism
A clinical trial published October 6, 2026, examined the use of lovastatin in 15 individuals diagnosed with neurofibromatosis type 1. The study found that the drug modulated theta band oscillations in the brain during emotional tasks.
Why it matters
The research investigates whether targeting GABA system alterations and Ras/MAPK pathway dysregulation can impact neurological symptoms associated with neurofibromatosis type 1. These findings offer insight into potential pharmacological interventions for the condition.
The study recorded brain activity in the 5-6 Hz theta band range, while noting no significant effects in the 8-11 Hz alpha or 13-20 Hz beta bands. Participants were administered 60 mg doses of either lovastatin or a placebo.
The players
National Institutes of Health
This primary federal agency conducts and supports medical research to improve human health and manage the clinical trial registry.
The details
Researchers utilized EEG technology to compute event-related spectral perturbations using Morlet wavelets during face recognition tasks. The results indicated that lovastatin successfully modulated theta band power in the specified frequency range.
Timeline
October 6, 2026: Findings were published regarding the clinical trial results.
The Big Picture
The study results represent a specific analysis conducted under the framework of NIH clinical trial registration #NCT03826940. This trial follows a pattern of investigating existing FDA-approved drugs for potential off-label neurological benefits.
This study does not suggest a change to current medical treatment protocols for patients with neurofibromatosis type 1. Patients should consult with their healthcare providers regarding any new medical research or potential off-label drug inquiries.
The takeaway
This study highlights the ongoing scientific effort to repurpose existing medications for neurological disorders. It emphasizes the necessity of rigorous clinical trials before determining the safety and efficacy of such treatments for specific patient populations.
Further reading
For broader context on neurodevelopmental research, see the Autism section.
More information
Review the full NIH clinical trial registration details for study parameters.
